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Background: The purposes of the present study are to evaluate a 
possible genetic factor determining sensitivity to EGFR alterations 
in cases of lung cancers, and also to verify whether such factor can 
be an indicator predicting molecular targeting drugs responsiveness. 
A CA dinucleotide repeats polymorphism of the ﬁrst intron of EGFR 
has recently been reported to be associated with occurrences of EGFR 
transcription in lung cancers, and with EGFR inhibitor responsiveness 
in head and neck cancers. We here examined this polymorphism for 
both tumor and non-tumor tissues of primary lung cancer cases, and 
have analyzed correlations of the polymorphism with EGFR altera-
tions Method: A hundred sixty nine lung tumors and corresponding 
normal parts were subjected to analyses. Locus of ﬁrst intron of EGFR 
covering CA-repeat stretch were PCR-ampliﬁed by using FAM-labeled 
primers. CA-repeats lengths were determined by acrylamide-gel elec-
trophoresis with DNA sequencer (SIMAZU DSQ). 
Results: We found that the constitutional shorter stretch of this repeats 
in the subjects was associated with occurrences of EGFR copy number 
gains (Chi-square test; P = 0.031) in tumors, and that the tumors having 
shorter stretch were more sensitive to geﬁtinib treatment (Chi-square 
test; P = 0.0241). 
Conclusions: We conclude that the CA dinucleotide repeat polymor-
phism can be a genetic factor inﬂuencing occurrences of EGFR copy 
number gains in tumors, and this observation entails the rationale for 
usage of this polymorphism for application of targeting therapy. 
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Background: Geﬁtinib and Erlotinib represent a new class of anti-neo-
plastic agents, the epidermal growth factor receptor (EGFR) Tyrosine 
Kinase inhibitors (TKI). By reversibly occupying the catalytic Mg-ATP 
binding site domain, they interrupt the signaling cascade initiated by 
EGFR stimulation resulting in decreased cell proliferation and survival. 
Clinical trials have demonstrated modest activity with minimal toxicity 
in the setting of advanced NSCLC. Ongoing experience suggests that 
patients who are female, Asian, non-smokers appear to beneﬁt most 
consistently from therapy. We performed a retrospective analysis of 
patients treated with these agents at the Tom Baker Cancer Centre 
(TBCC) to determine if our experience reﬂects this observation.
Methods: The pathology, radiologic records, laboratory investiga-
tions and medical records of 65 patients treated with the EGFR TKIs 
Erlotinib or Geﬁtinib between May 2002 and June 2006 were reviewed. 
Complete or partial radiologic response (CR, PR), stable and progres-
sive disease (SD, PD) were deﬁned as per RECIST criteria. Partial 
response in non-measurable radiologic disease was characterized as 
regression of lymphangitic carcinomatosis. Symptomatic response was 
deﬁned as decreased shortness of breath or pain, decreased FiO2 or 
improvement in ECOG performance status. 
Results: 65 patients, 45 treated with Geﬁtinib, 17 with Erlotinib as 
a ﬁrst EGFR TKI were included; another 3 patients were treated on 
the BR-21 protocol (Erlotinib vs. placebo) as a ﬁrst EGFR TKI and 
subsequently received Geﬁtinib after progressing. 5 patients treated 
with Geﬁtinib as a ﬁrst EGFR TKI, were later treated with Erlotinib. 
Baseline characteristics of the 45 patients treated with Geﬁtinib; 24% 
Asian, 73% Caucasian; 60% female; 29% life long non-smokers, 42% 
ex-smokers, 29% smokers; 56% adenocarcinoma, 13% squamous, 2% 
adenosquamous, 7% large cell, 9% BAC and 13% unknown. 1 patient 
achieved a CR, 6 (13%) had a PR, 16 (36%) had SD with 22 (49%) 
showing PD. Clinically, 13 (29%) patients experienced symptomatic 
improvement, 15 (33%) reported no change, and 17 (38%) patients ex-
perienced symptomatic decline. The 7 responders were predominantly 
non-smoking Asian women with adenocarcinoma. Of the 17 patients 
treated with Erlotinib as a ﬁrst EGFR TKI, baseline characteristics 
were; 24% Asian, 76% Caucasian; 76% female; 41% life long non-
smokers, 29.5% ex-smokers, 29.5% smokers; 65% adenocarcinoma, 
23% squamous, 6% BAC, and 6% other. 2 (12%) patients had a PR, 7 
(41%) had stable disease and the other 8 (47%) patients progressed on 
treatment. Symptomatically, 7 (41%) patients experienced improve-
ment, 6 (35%) had no change, and 4 (24%) experienced symptom 
progression. Both responders were female non-smokers with adenocar-
cinoma, however one was Asian, the other Caucasian. 
Conclusions: At the TBCC, in a select number of patients with ad-
vanced NSCLC, both EGFR TKI’s demonstrated clinical and radio-
logic anti-tumor activity with minimal side effects. The responders to 
both drugs at our institution were predominantly female, non-smoking 
Asians with adenocarcinoma. Our experience in a Canadian setting 
supports the impression that this constellation of clinical characteristics 
is a useful, though not speciﬁc, predictor of response to these agents. 
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Background: Erlotinib (TARCEVA®) is an oral, epidermal growth 
factor receptor (EGFR) tyrosine kinase inhibitor that has anti-tumor 
activity and good tolerability in non-small cell lung cancer (NSCLC). 
In particular, higher response rates have been noted in Oriental patients 
than Western patients. The aim of this study (EAP; Expanded Ac-
cess Program) is to evaluate the efﬁcacy and tolerability of erlotinib 
monotherapy as a palliative treatment for advanced NSCLC patients in 
Korea. 
Material and Methods: Patients with histologically or cytologically 
conﬁrmed stage IIIB or IV NSCLC including recurrent, or metastatic 
disease, with performance status from 0 to 3, were eligible either if they 
had received any anti-cancer treatment except EGFR inhibitors or if 
they were unsuitable for chemotherapy due to poor performance status. 
Enrolled patietns were treated with oral erlotinib, at a dose of 150 mg 
daily until disease progression or development of intolerable toxicity. 
Results: The median age of the 120 patients was 61 years, and 63.3% 
were male; 89.1% were performance status 0-1; 50.8% had received 
one prior palliative chemotherapy regimens and 33.3% were two or 
more prior palliative regimens. Overall tumor response rate, including 
complete and partial response, was 23.3% and an additional 18.3% 
of patients achieved stable disease. Superior tumor responses were 
observed in females (p=0.001), never-smokers (p=0.047), and histology 
of adenocarcinoma (p<0.001). The most common adverse event was 
skin rash (78%), which were generally mild, but grade 3/4 skin rash 
occurred in 13% of all enrolled patietns. There is one treatment related 
mortality with pneumonia. With a median follow-up of 14.5 months, 
the median time to progression (TTP) was 2.7 months (95%CI; 2.2-3.2) 
and the median overall survival (OS) has not been reached yet. Female 
(p<0.001), adenocarcinoma (p=0.01), never-smoker (p<0.001), and ap-
pearance of skin rash (p<0.001) were good prognostic factor for overall 
survival. In multivariate analysis, female gender and presented skin 
rash were better prognostic factors for survival. 
Conclusion: Erlotinib monotherapy showed clinically signiﬁcant 
anti-tumor activity and an acceptable tolerability proﬁle as a palliative 
treatment in advanced NSCLC patients in Korea, especially in females, 
never-smokers, patients with adenocarcinoma histology, and in cases 
with skin rash. 
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Background: Mutations in epidermal growth factor receptor (EGFR) 
are considered as a strong predictive marker to EGFR tyrosine kinase 
inhibitors (TKIs) in non-small-cell lung cancer (NSCLC). Recent stud-
ies suggested EGFR status may change between primary tumor and 
corresponding metastatic site. However, it has not fully been evaluated 
whether EGFR mutation differs in metastases compared to primary 
NSCLC.
Methods: In total, 128 tumor samples from 64 NSCLC patients who 
underwent surgery between 1996 and 1999 were investigated compar-
ing matched 64 primary tumors, and 64 lymph node metastases. The 
epidermal growth factor receptor mutation status was analyzed by a 
direct sequencing method (exons 18-21 in EGFR) on tumor samples of 
primary NSCLC and corresponding lymph node metastasis.
Results: In 17.2% of patents (11/64), EGFR mutation was identiﬁed in 
either primary NSCLC or metastasis by DNA sequencing. Six (54.5%) 
out of eleven cases showed discordance of EGFR mutation in the 
primary tumor/metastasis site. Two cases showed EGFR mutation in 
the metastasis but not in the primary tumor, while, in four cases, EGFR 
mutation was detected in the primary tumor but not in the metastasis 
site. The majority of discordance of EGFR mutations was identiﬁed 
in exon 19 (83.3%, 5/6). The median overall survival (OS) was 17.7 
months (95% conﬁdence interval, 9.4-20.0). Median OS was not varied 
by the discordance of EGFR mutation status between primary NSCLC 
and corresponding metastatic site.
Conclusions: These results suggest that the status of EGFR mutation 
in primary NSCLC and that in corresponding metastasis site varied in 
considerable cases by direct DNA sequencing. Whether the status of 
EGFR mutation changes during the process of metastasis remains to be 
investigated. The data will be updated with larger number of speci-
mens. 
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Background: Epidermal growth factor receptor (EGFR) muta-
tions have been reported to be related to geﬁtinib responsiveness in 
non-small cell lung cancer (NSCLC). This exploratory analysis was 
performed within a prospective phase II study to determine the associa-
tion of EGFR mutations with clinical characteristics and outcome in 
NSCLC patients who were treated with geﬁtinib.
Methods: We analyzed the incidence of EGFR mutations in NSCLC 
specimens from 68 Korean patients who were treated with geﬁtinib 
(43 patients as second-line and 25 as third-line therapy) in a prospec-
tive study. Thirty-nine tumor tissue samples were obtained from these 
patients and analyzed for EGFR mutations (exons 18 to 21). The 
molecular alterations were compared with clinical characteristics and 
outcomes.
Results: EGFR mutations were found in 7 (18%) out of 39 patients, 
including in-frame deletions within exon 19 (n=3) and L858R missence 
mutaions in exon 21 (n=4). For the 7 patients with EGFR mutations, 6 
were male, 6 were current/former smoker, and 4 had adenocarcinoma. 
Higher rate of response to geﬁtinib was noted in patients with EGFR 
mutations compared to those with wild-type EGFR (86% vs. 16%, 
respectively; p=0.001). Using a multiple logistic regression model 
performed by entering all predictive factors as covariates, only the 
